Aim: To compare the overall survival (OS) among patients who received first-line modified gemcitabine plus nab-paclitaxel (G/nab-P) or 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) for metastatic pancreatic cancer. Methods: A single-center, retrospective, real-world study was conducted. Results: The median OS was 9.4 months versus 7.5 months in the mFOLFIRINOX and modified G/Nab-P groups, respectively (p = 0.16). An exploratory subgroup analysis excluding patients who received one infusion and had an Eastern Cooperative Oncology Group performance score of 2 demonstrated similar OS of 11.3 months and 8.9 months, respectively. Median progression-free survival and time-to-treatment failure were not significantly different. Higher rates of adverse events were noted with mFOLFIRINOX. Conclusion: mFOLFIRINOX did not significantly prolong OS compared with modified G/nab-P and was associated with increased toxicities.
Keywords: FOLFIRINOX; gemcitabine; metastatic pancreatic adenocarcinoma; nab-paclitaxel; real-world evidence; survival.
Pancreatic cancer that has spread to other parts of the body cannot be cured and patients usually have a limited time to live after diagnosis. It is therefore important to choose an effective treatment while minimizing the side effects of chemotherapy and maintaining patients' quality of life. Initial chemotherapy regimens include a combination of gemcitabine plus nab-paclitaxel (G/nab-P) or 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX). While some studies have found that patients treated with FOLFIRINOX may live longer, they also experience more side effects. This single-center study showed that patients treated with modified G/nab-P and FOLFIRINOX regimens had similar survival outcomes but FOLFIRINOX was associated with increased toxicities.